

- **Name:** Dejan Juric
  - **Current Position & Affiliation:** Assistant in Medicine, Massachusetts General Hospital
  - **Country:** USA
- 

• **Educational Background:**

1995 – 2001 M.D., Medicine, University of Zagreb

• **Professional Experience:**

10/01-09/02	Intern	Internal Medicine (Primary University Medical Center mentor/PI: Boris Labar, MD, Zagreb PhD)
10/02-05/07	Postdoctoral Research Fellow in Oncology	Cancer Biology and Genomics (Primary mentor/PI: Branimir Sikic, MD) Stanford University
06/07-06/09	Resident	Medicine Massachusetts General Hospital
06/09-06/12	Clinical and Medical Oncology Research Fellow	Dana Farber Cancer Institute/Partners CancerCare
07/12-	Instructor in Medicine	Medicine Harvard Medical School

**Appointments at Hospitals/Affiliated Institutions:**

07/12-	Assistant in Medicine	Medicine Massachusetts General Hospital
--------	-----------------------	---

• **Professional Organizations:**

2019-	Scientific Advisory Board Member	MapKure	1 hour per month.
2019-	Scientific Advisory Board Member	Vibliome Therapeutics	1 hour per month.
2020-	Scientific Advisory Board Member	Relay Therapeutics	2 hours per month.

2021-	Scientific Advisory Board Member	PIC Therapeutics	2 hours per month.
2021-	Scientific Advisory Board Member	Transcode Therapeutics	1 hour per month.

• **Main Scientific Publications:**

1. Pirruccello JP, Chaffin MD, Chou EL, Fleming SJ, Lin H, Nekoui M, Khurshid S, Friedman SF, Bick AG, Arduini A, Weng LC, Choi SH, Akkad AD, Batra P, Tucker NR, Hall AW, Roselli C, Benjamin EJ, Vellarikkal SK, Gupta RM, Stegmann CM, Juric D, Stone JR, Vasani RS, Ho JE, Hoffmann U, Lubitz SA, Philippakis AA, Lindsay ME, and Ellinor PT. Deep learning enables genetic analysis of the human thoracic aorta. *Nat Genet.* 2021 Nov 26. <https://doi.org/10.1038/s41588-021-00962-4> PMID: 34837083.
2. Brastianos PK, Strickland MR, Lee EQ, Wang N, Cohen JV, Chukwueke U, Forst DA, Eichler A, Overmoyer B, Lin NU, Chen WY, Bardia A, Juric D, Dagogo-Jack I, White MD, Dietrich J, Nayyar N, Kim AE, Alvarez-Breckenridge C, Mahar M, Mora JL, Nahed BV, Jones PS, Shih HA, Gerstner ER, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, and Sullivan RJ. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. *Nat Commun.* 2021 Oct 12;12(1):5954. PMID: 34642329.
3. Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, Danysh BP, Slowik K, Jacobs RA, Rhrissorakrai K, Utro F, Levovitz C, Denault E, Walmsley CS, Kambadakone A, Stone JR, Isakoff SJ, Parida L, Juric D, Getz G, Bardia A, and Ellisen LW. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. *Cancer Discov.* 2021 Oct;11(10):2436-2445. PMID: 34404686.
4. Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, and Reynolds KL. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. *J Immunother Cancer.* 2021 Sep;9(9):. PMID: 34544895.
5. Jhaveri K, Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, and Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. *Clin Cancer Res.* 2021 Aug 25. PMID: 34433648.
6. Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, Eilers-Lenz B, Tian H, Xiong W, Kaleta R, and Kurzrock R. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. *J*

Hematol Oncol. 2021 Aug 18;14(1):127. PMID: 34407844.

7. Spring LM, Clark SL, Li T, Goel S, Tayob N, Viscosi E, Abraham E, Juric D, Isakoff SJ, Mayer E, Moy B, Supko JG, Tolaney SM, and Bardia A. Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. *NPJ Breast Cancer*. 2021 Aug 4;7(1):103. PMID: 34349115.
8. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, and Corcoran RB. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. *Cancer Discov*. 2021 Aug;11(8):1913-1922. PMID: 33824136.
9. Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe Å, Abbondanza D, Fleming SJ, Subramanian A, Montoro DT, Jagadeesh KA, Dey KK, Sen P, Slyper M, Pita-Juárez YH, Phillips D, Biermann J, Bloom-Ackermann Z, Barkas N, Ganna A, Gomez J, Melms JC, Katsyv I, Normandin E, Naderi P, Popov YV, Raju SS, Niezen S, Tsai LT, Siddle KJ, Sud M, Tran VM, Vellarikkal SK, Wang Y, Amir-Zilberstein L, Atri DS, Beechem J, Brook OR, Chen J, Divakar P, Dorceus P, Engreitz JM, Essene A, Fitzgerald DM, Fropf R, Gazal S, Gould J, Grzyb J, Harvey T, Hecht J, Hether T, Jané-Valbuena J, Leney-Greene M, Ma H, McCabe C, McLoughlin DE, Miller EM, Muus C, Niemi M, Padera R, Pan L, Pant D, Pe'er C, Pfiffner-Borges J, Pinto CJ, Plaisted J, Reeves J, Ross M, Rudy M, Rueckert EH, Siciliano M, Sturm A, Todres E, Waghray A, Warren S, Zhang S, Zollinger DR, Cosimi L, Gupta RM, Hacoheh N, Hibshoosh H, Hide W, Price AL, Rajagopal J, Tata PR, Riedel S, Szabo G, Tickle TL, Ellinor PT, Hung D, Sabeti PC, Novak R, Rogers R, Ingber DE, Jiang ZG, Juric D, Babadi M, Farhi SL, Izar B, Stone JR, Vlachos IS, Solomon IH, Ashenberg O, Porter CBM, Li B, Shalek AK, Villani AC, Rozenblatt-Rosen O, and Regev A. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature*. 2021 Jul;595(7865):107-113. PMID: 33915569.
10. Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, and André F. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. *J Clin Oncol*. 2021 Jun 20;39(18):2005-2015. PMID: 33780274.